- Elway joins campaign aimed at encouraging those who think they
may have Dupuytren's contracture to seek a diagnosis from a hand
specialist and ask about treatments, including nonsurgical
options
- The common yet little-known hand condition affects nearly the
same number of American adults diagnosed with major
depression
DUBLIN and MALVERN, Pa., Aug. 22,
2019 /CNW/ -- Hall of Fame Quarterback John Elway is teaming up with Endo
Pharmaceuticals Inc. to raise awareness of a common yet
little-known hand condition called Dupuytren's contracture and
available treatment options. John has Dupuytren's contracture in
both of his hands and he is now sharing his story as part of a
national education campaign called Facts on Hand. The
campaign aims to educate Americans and to support the Dupuytren's
contracture community by helping them become more informed about
the condition and feel empowered to talk with a hand specialist
about all treatments, including nonsurgical options.
Experience the interactive Multichannel News Release here:
https://www.multivu.com/players/English/8568151-endo-facts-on-hand-dupuytrens-contracture/
Dupuytren's contracture is a progressive hand condition that
affects an estimated 16 million Americans. It is characterized by a
buildup of collagen underneath the skin on the palms of the hand,
causing one or more fingers to move into a bent position so they
cannot be straightened. Because the condition can progress slowly,
people may not pay attention to it until they can no longer
straighten their fingers, complicating everyday activities – from
writing one's name to shaking hands.
"My hands are everything to me, but when I was diagnosed with
Dupuytren's contracture nearly 15 years ago, I waited to get
treatment because I assumed surgery was my only option," said
Elway. "I've joined the Facts on Hand campaign not only to
raise awareness about Dupuytren's contracture by sharing my story,
but to spread the word about available treatments. Some people also
mistakenly believe that surgery is their only option – but that may
not be true. That's why it's so important to have a conversation
with a hand specialist."
Dupuytren's contracture can be mistaken for other conditions
such as arthritis or trigger finger. Prior to the formation of a
contracture, individuals may start to notice symptoms through the
development of a lump or nodule on the palm. The condition most
commonly impacts the ring and pinky finger and can occur in one or
both hands.
"There is still so little awareness about Dupuytren's
contracture, even among doctors," said Damon Adamany, MD, board-certified specialist in
hand and upper extremity surgery at The CORE Institute. "It's
important that those experiencing the condition know their
treatment options. Surgery is not the only option, and patients
should work together with their hand specialist to determine the
best approach for their lifestyle, whether they're a football star
or a weekend warrior."
Typically, men are affected by Dupuytren's contracture more
often than women. The condition usually appears later in life in
people over age 40, although it may occur in people who are in
their early 20s.
The cause of Dupuytren's contracture is unknown. The condition
can run in families, especially those of Northern European
descent.
"At Endo, we have a longstanding commitment to educating
consumers about Dupuytren's contracture," said Patrick Barry, Executive Vice President and
Chief Commercial Officer, U.S. Branded Pharmaceuticals at Endo. "As
we continue to further our Facts on Hand initiative, we're
hoping to shed more light on this condition and improve the lives
of the patients we serve."
For more information, visit www.FactsOnHand.com.
About Endo International plc
Endo International plc
(NASDAQ: ENDP) is a highly focused generics and specialty branded
pharmaceutical company delivering quality medicines to patients in
need through excellence in development, manufacturing and
commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in
Malvern, PA. Learn more at
www.endo.com.
About Endo Pharmaceuticals Inc.
Endo Pharmaceuticals
Inc., headquartered in Malvern,
PA, develops and markets high-value, quality branded
pharmaceutical products for patients in need. Endo Pharmaceuticals'
specialty portfolio includes products for urology, men's health,
orthopedics and endocrinology, with product development underway in
medical aesthetics. Endo Pharmaceuticals is an operating company of
Endo International plc. Learn more at www.endo.com or
www.endopharma.com.
Cautionary Note on Forward-Looking Statements
This
press release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
Canadian securities legislation, including, but not limited to,
statements by Messrs. Elway and Barry and Dr. Adamany. Statements
including words such as "believes," "expects," "anticipates,"
"intends," "estimates," "plan," "will," "may," "look forward,"
"intend," "guidance," "future" or similar expressions are
forward-looking statements. Because these statements reflect our
current views, expectations and beliefs concerning future events,
these forward-looking statements involve risks and uncertainties.
Although Endo believes that these forward-looking statements and
information are based upon reasonable assumptions and expectations,
readers should not place undue reliance on them, or any other
forward looking statements or information in this press release.
Investors should note that many factors, as more fully described in
the documents filed by Endo with securities regulators in
the United States and Canada including under the caption "Risk
Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings, as
applicable, with the Securities and Exchange Commission and with
securities regulators in Canada on
System for Electronic Document Analysis and Retrieval ("SEDAR") and
as otherwise enumerated herein or therein, could affect Endo's
future financial results and could cause Endo's actual results to
differ materially from those expressed in any forward-looking
statements. The forward-looking statements in this press release
are qualified by these risk factors. Endo assumes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future developments or otherwise, except as may
be required under applicable securities law.
Endo International
plc:
Media:
Heather Zoumas-Lubeski
(484) 216-6829
Investors:
Pravesh Khandelwal
(845) 364-4861
View original
content:http://www.prnewswire.com/news-releases/football-legend-john-elway-reveals-he-has-dupuytrens-contracture-and-wants-others-to-get-the-facts-on-hand-300905245.html
SOURCE Endo International plc.